Bioniche Responds to Australian Equine Influenza Outbreak



    - Equimune(R) IV product a proven treatment -

    BELLEVILLE, ON, Sept. 6 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that it has increased its supply of Equimune(R)IV to Australia in
order to be able to respond to anticipated increased demand as a result of
that continent's equine influenza outbreak. The outbreak began in August, and
according to one media report, a total of 3,376 horses on 405 properties are
now suspected of having the virus.
    "Bioniche wants to ensure that sufficient supply of Equimune IV is
available to Australian veterinarians," said Jim Phillips, President of
Bioniche Animal Health (global). "At the same time, we are ensuring that
veterinarians have the information they require about our proprietary
immunotherapy product and its efficacy in the treatment of equine influenza."
    Equine influenza is a viral respiratory infection that causes flu like
symptoms in horses and is from the group of viruses that causes flu in humans.
Most horses exposed to the virus will show signs within a period of 1-5 days.
Most viruses that are responsible for coughs and colds in horses result in
mild symptoms, such as nasal discharge and coughing. Equine Influenza produces
more severe symptoms, with horses developing a fever and a dry hacking cough.
Horses become ill and are reluctant to eat or drink for several days, but
usually recover in 2 to 3 weeks. The virus can be spread easily from horse to
horse as a result of droplets and also from nasal discharge and from things
like infected brushes and rugs. The disease is very contagious and there can
be an almost 100% infection rate in a population that has been previously
unexposed to the virus.
    Australia and New Zealand are the only countries with significant equine
industries that have been previously free from equine influenza. Horses in
Australia are not vaccinated. This outbreak of equine influenza is expected to
have a major impact on the multibillion-dollar equine stud and racing
industries. Quarantine programs have been developed for the safe movement of
horses internationally for breeding, racing, and other purposes. Increased
international movement of horses for breeding and competition purpose
constitutes an important factor in the spread of equine influenza throughout
the world.
    "Equimune IV has been an excellent tool used in our practice both to
treat viral respiratory infections and as a preventative aid used in the face
of an outbreak," said Dr. Richard C. Mather II, DVM of the Woodland Run Equine
Clinic in Grove City, Ohio. "For best results, we advise that horses not be
stressed for 24 hours following treatment with Equimune IV."

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
195 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. For more information, please visit www.Bioniche.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF




For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890